adult clinical studies

There's been a lot of comments on the Charting thread regarding share price projections following the upcoming release of adult clinical study results.  For the most part, I hate to burst you bubble guys but I doubt very much if we'll see some of the valuations many of you are hoping for (at least not just yet).  I use the past as a predictor of the future.  On 03/03/2016 RAP announced "breakthrough performance in paediatric clinical study" (see below).  The closing share price was 0.13 prior to the announcement and 0.19 after the announcement, representing a 41%  gain.  Therefore IF adult clinical study results are as good as the paediatric clinical study results and assuming the closing share price before the announcement is 0.40, we may see a 41% gain and a closing share price of 0.56.  I believe further inflation of the market cap/share price will come with commercialisation of the technology and/or FDA approval.  It's worth noting that when ResApp announced "updated paediatric clinical study results" the share price went down 4%.  Good luck to all, and lets try to keep the Charting thread for what it was intended. Cheers.